The present study is an attempt to develop bilayer matrix tablets of Nebivolol Hydrochloride and Valsartan with immediate release for Nebivolol Hydrochloride and sustained release for Valsartan. Superdisintegrants such as sodium starch glycolate and Crosscarmellose sodium were evaluated for immediate release of Nebivolol Hydrochloride and polymers HPMC K100M and K4M for sustained release of Valsartan. Preformulation studies were performed prior to compression. The compressed bilayer tablets were evaluated for w eight variation, thickness, hardness, friability, drug content and in vitro drug release using USP dissolution apparatus type 2 in 0.01N HCl and phosphate buffer pH 6.8. All the pre and post compression parameters were found to be within the acceptable limits. The results of dissolution show that the formulations B3 was the best of all immediate and sustained release layer batches. The release kinetics of Valsartan was subject to curve fitting analysis in order to identify the best fit kinetic model. The regression analysis proves that the best formulations follow zero order release and drug release by diffusion process based on Fick's law of diffusion. The data for stability studies infer no considerable change in drug co ntent and dissolution rates as per ICH guidelines. The best formulation B3 was subjected to in vivo pharmacokinetic studies in rabbit model. In vitro, In vivo correlation (IVIVC) showed considerable linearity. Hence a novel bilayer tablet formulation of Nebivolol Hydrochloride and Va lsartan was successfully developed by combining both immediate (IR) and sustained (SR) release layers.
INTRODUCTION
Developing a new molecule is expensive and time consuming. Other alternative .other alternative methods such as individualizing drug therapy, dose titrations, therapeutic drug monitoring and novel drug delivery system, using old drug by improving safety and efficacy ratio, brings out promising results. Successes in drug delivery research are the result of concerned efforts by the scientist of variety of disciplines who recognize the need and potentiate for improving pharmcotherapeutics through the development of novel drug delivery systems.
The drug delivery systems are usually known by terms like sustained, controlled, targeted, smart, intelligent, novel, therapeutics and programmed. However the basic rationale for these varied delivery modules is the alteration or manipulation of the pharmacokinetic and pharmacodynamics of pharmacologically active moieties. This can be achieved through novel drug delivery devices. 1 Essential or primary hypertension is a persistent elevation of blood pressure which is not caused by underlying cardiac, endocrine or renal diseases.2 Approximately 70% of blood pressure elevations in youth represent early onset of essential hypertension. 2, 3 Attaining a target blood pressure can be very difficult with monotherapy especially in case of patients with multiple drug therapy. A survey on trends in the use of antihypertensive agents in France from 2002 to 2012 supported the view of suboptimal treatment for hypertension with monotherapy and hence prescriptions of fixed dose combinations from 19% to 30%. 3 Fixed dose combination refers to the combination of two or more active ingredients in a single pharmaceutical formulation. 4 A number of clinical trials show that most hypertensive patients were unlikely to achieve a normal pressure by taking single drug for a quite a long time. 5 Formulation technologies such as multilayer tablets, multiparticulate systems, active film coating and hot melt granulation are developed in the design of formulation. Reviews of physicians' desk reference show that infectious, cardiovascular, hormones, allergies and pain are the top most five medical areas for fixed dose combinations 0f oral dosage forms, nevertheless hypertension treatment takes 80% in cardiovascular. 6 
Rationale for drug selection
Valsartan is an angiotensin II receptor antagonist that is used in the treatment of hypertension. It act by blocking the binding of angiotensin II and I to its receptors thereby blocking vasoconstrictor and aldosterone secreting effect of angiotensin II selectively. The most preferred route for this drug is oral delivery in the form of tablets. Valsartan has poor water solubility, low bioavailability (approximately 20-25%) and short half-life (nearly hrs.) which makes it an ideal candidate for sustained release. Hence in the present work this ideology is adopted. 7 Nebivolol is a novel beta1-blocker with a greater degree of selectivity for beta1-adrenergic receptors than other agents in this class and a nitric oxide (NO)-potentiating, vasodilatory effect that is unique among beta-blockers currently available to clinicians .A NO-potentiating agent such as Nebivolol may have an important role in hypertensive populations with reduced endothelial function such as diabetics, Nebivolol is unique among beta blockers in that, at doses <10 mg, it does not inhibit the increase in heart rate normally seen with exercise. The efficacy of Nebivolol has been tested successfully in clinical trials against other agents including other beta-blockers, angiotensin-converting enzyme-inhibitors and calcium channel antagonists in patients with hypertension, angina, and congestive heart failure. The tolerability of Nebivolol has been shown to be superior to that of atenolol and Metoprolol. 8 Multilayer tablets give a successful development of controlled release formulation and provide a way of successful drug delivery system. Conventional dosage form sometimes leads to undesirable toxicity and poor efficiency due to fluctuation in concentration in blood tissues.
For the current research Nebivolol Hydrochloride in immediate release and Valsartan in sustained release layer was selected as fixed dose combination for bilayer tablet technology. Recently, fixed dose combination of Nebivolol hydrochloride, a selective β1 antagonist and valsartan an angiotensin II receptor blocker was approved by USFDA for hypertension. Pharmacological profiles of Nebivolol hydrochloride and valsartan alone and in combination are well characterized. In addition, a large 8-week randomized trial in stages I-II hypertensive patients (N=4161) demonstrated greater blood pressure-reducing efficacy for 33Neb/valsartan SPCs than component monotherapies with comparable tolerability. In a biomarkers sub study (N=805), Nebivolol/valsartan single-pill combination prevented valsartan-induced increases in plasma renin, and a greater reduction in plasma aldosterone was observed with the highest single-pill combination dose vs. valsartan 320 mg/day. 9 
MATERIALS AND METHODS

Formulation of Bi-layer tablets:
The ingredients after sifting, Prelubrication and blending was subjected for precompression parameters like excipient compatibility studies (Table 1, 
Preparation of Nebivolol Hydrochloride immediate release (IR) layer:
The active Ingredient Nebivolol hydrochloride and diluents Micro crystalline cellulose (Avicel PH 102), Dibasic calcium Phosphate (anhydrous, FCC), were sifted through 40 mesh sieve. Sodium Starch Glycolate(731713H), Croscarmellose sodium (Ac di sol NF),were sifted through 60 mesh sieve. FD&C blue lake, was sifted through 100 mesh sieve.
Dry mixing: Mix geometrically Nebivolol hydrochloride with
Micro crystalline cellulose (Avicel pH 102), Dibasic calcium Phosphate, Disintegrants (SSG or CCS) and FD&C blue lake, were taken in a poly bag and mixed for 15minutes to ensure uniform mixing of the ingredients with the drug.
Preparation of Valsartan sustained release (SR) layer:
The active ingredient Valsartan, was passed through the 40 mesh sieve followed by the other ingredients were passed the same sieve. 
Lubrication and compression of Bilayer tablets:
Magnesium stearate, was weighed and were passed through 60 mesh sieve. Then mixed with dried granules of Valsartan and Nebivolol Hydrochloride separately in a polybag for 5minutes to get a uniform blend. Then the lubricated granules of Valsartan and Nebivolol Hydrochloride were added in the separate hopper in double rotary punching machine and compressed into Bilayer tablets using 13.5X.7.5mm oblong shape punches, at target weight of 300 mg.
The stock standard solution of Nebivolol and Valsartan were prepared by dissolving accurate amount of the drugs initially in methanol and diluted with 6.8 ph. phosphate buffer to get the first stock solution. From this stock solution series of dilutions were made to get a concentration range of 5-100 ppm. A linearity graph was obtained by measuring the absorbance of the series of dilution of the drugs at 281 nm and 251 nm for Nebivolol hydrochloride and valsartan respectively. 
In vitro dissolution study 12
The in vitro dissolution of Nebivolol Hydrochloride and Valsartan bilayer tablets were determined using USP XXIII (basket method) dissolution apparatus. The basket was allowed to rotate at a speed of 50 rpm and temperature of 37 ± 0.5°C was maintained. The dissolution medium used was 900 ml of 0.1N HCl (pH 1.2) for the initial 2hours followed by study in simulated intestinal fluid Phosphate buffer solution (pH 6.8). Aliquots (5 ml) of sample were collected at predetermined time intervals (1, 4, 8, 20, 24 hrs.) from the dissolution apparatus and it was replaced with equal volume of fresh dissolution medium. The aliquots withdrawn were filtered through 0.45µm millipore filters. The concentration of both the drugs in the dissolution media was estimated by UV spectrophotometric method at 281 nm and 251nm for Nebivolol hydrochloride and Valsartan respectively. 
Interpretation of the kinetic studies:
 The r value for zero order release indicates the SR layer containing valsartan follows zero order release pattern where in the drug release at any moment is independent of the initial concentration.

The r value for Higuchi model infers the SR layer follows a drug release by diffusion process based on Fickian law of diffusion.
The r value for Peppas model shows no linearity.
The r value for Hixon Crowell value indicates no linearity and hence proves that the drug release from SR layer is not by dissolution.
In vivo pharmacokinetic studies: 13 An in vivo pharmacokinetic study was carried out according to ethical guidelines for investigations in laboratory animals and approved by the Institutional Animal Ethics Committee (IAEC) reference No. in vivo/041.All procedures and care of the rabbits were in accordance with institutional guidelines for animal use in research. Four healthy male albino rabbit weighing 2-2.5 were fasted overnight. Tablets were administered orally. Rabbits were held in rabbit restrainers during blood sampling. Blood samples were collected from marginal ear veins at predetermined intervals of 0, 0.5, 1, 2, 3, 4, 6, 8, 20 and 24 h post dose into heparinized tubes. Plasma samples were obtained following centrifugation of blood and kept frozen at -20 degree until analysis until liquid chromatography/mass spectrometry (LC/MS-MS) analysis. An ionization was checked in both the ionization mode (Positive and negative mode) and it was observed that Valsartan was shown good ionization in negative mode (deprotonated) and Nebivolol and Phenacetin (IS) were given good intense response in positive ionization mode (protonated).
Standard curve:
A stock cocktail solution (containing Nebivolol and Valsartan) ranging from 1000 -0.312 µg/ml was prepared using LC-MS grade methanol. Further this was diluted to obtain a working standard solution ranging from 25.9ng/ml to 83000ng/ml. The dilution was performed by pipetting 33.2µL separately from each stock and making up the volume to 200µL using untreated plasma and mixed by vortex for 30 seconds. After 10 minutes of incubation, 10µL of (25ppm) Phenacetin (internal standard) was added and vortex for 30 seconds. 600µL of methanol was added to precipitate the proteins. The samples were subjected to centrifugation at 8000rpm for 5 minutes at 15ºC. The supernatant was separated and subjected to LC-MS/MS analysis.
Procedure:
To the assay vial, 200µl of rabbit plasma was added followed by addition of 10 µl of internal standard Phenacetin at the concentration of 25ppm. 600 µl of 0.1% formic acid in methanol was added to precipitate the plasma contents mixed by vortex for 30 seconds. The above samples were subjected to vortex for 30 seconds followed by centrifugation at 8000rpm for 5 minutes at 15°C. The supernatant was collected and subjected to LCMS analysis. The pharmacokinetic parameters were estimated using Phoenix WinNonlin® (Version 8.1, USA). 
In vitro In vivo correlation (IVIVC)
Recently, application of IVIVC has been suggested in the pharmaceutical field for development of novel formulations to reduce the time and cost of manufacturing. 14 The FDA has developed a regulatory guidance for both immediate and modified release dosage forms, thus minimizing the need for bioavailability studies as a part of the formulation design and optimization process. Among the poorly water soluble drugs, BCS class II drugs could be applied to IVIVC, since dissolution is the rate limiting step for drug absorption in gut. 15 This concept holds good for Nebivolol Hydrochloride which belong to BCS class II, also an immediate release layer of this drug would further enhance the dissolution there by improving absorption. Though Valsartan belongs to BCS class IV, it behaves as BCS class III drug since it shows good solubility in intestinal Ph. hence can be considered for IVIVC. Stability studies 16 In the present analysis, stability studies were carried out for both at room temperature and accelerated stability conditions. The conditions for storing at room temperature were kept as 30±2 °C and 65±5% RH and for accelerated stability conditions were kept at 40±2°C and 75±5% RH in a humidity chamber. At regular intervals of time (0, 2, 4 and 6 months) samples were withdrawn and evaluated for drug content and in-vitro release profile. All the parameters were within the acceptable limits.
RESULTS AND DISCUSSION
Various formulations of Bilayer tablets were prepared and evaluated with an aim to develop Valsartan as sustained release layer and Nebivolol Hydrochloride as an immediate release layer for improving hypertension therapy of two drugs and also patient's compliance. To minimize the critical process parameters, direct compression method was selected for the formulation. The polymers and other excipients were selected based on the satisfying results produced during Drug-Excipients compatibility studies to develop the final formulation (Table 1&2 ). Results show the compatibility of drug with the excipients. The physicochemical evaluation results for the granules of all trials pass the official limits with respect bulk and tapped density, angle of repose, Carr's index ans hausners' ratio ( Table 3 ). In present work a bulk density in the range of 0.5 -0.6 gm/cm3indicates a good packing characteristics. The Carr's compressibility index was found to be in the range of 23 % which suggested optimal compressibility. The values of hausner ratio where found in the range of 1.30 suggested optimal flowability of powder blend. The angle of repose of all the blend was within range of 28 to 28 indicated excellent flow property of powder blend. The bilayer tablets were evaluated for different physical parameter. The hardness of bilayer tablet was found in the range of 12 to 17 kg/cm2 which was more as compare to individual layer because of double compression. The thickness of the bilayer tablet was in the range of 3 -4 mm which is an excellent value for double layer. The friability was 0.54 -0.58% for bilayer tablet which was less than 1 indicating good handling of tablet. The weight variation study showed low standard deviation uniformity in weight of the tablets 300 ± 0.06mg. 17 In the formula of Nebivolol Hydrochlioride immediate release layer, super disintegrants sodium starch glycolate and Croscarmellose sodium were used 4 mg per tablet. The results of drug release from IR layer, infers that at the concentration of 4 mg both the super disintegrants comply with the limit for drug release in 30 min (Table:9 , fig 4) . In the formula for Valsartan sustained release layer, Hydroxypropyl Methyl Cellulose (HPMC K 100 M) and HPMC K 4M were used as retardant polymers. From the drug release profile it infers that Hydroxypropyl Methyl Cellulose (HPMC K 100 M) at a concentration of 50 t0 60% produced desired release profile for Valsartan extended release layer as per USP limits. B3 was considered the best formulation based on the release profile of both the drugs in immediate and sustained release layer. (Table: 10, fig 3&3A) . To analyze the pattern of drug release, the drug release data of the best formulations were subject to release kinetics studies. (Table  10) The results show that formulation B3 depicts zero order release pattern in which the prime mechanism is diffusion controlled release. B3 optimized tablets was selected for accelerated stability studies for a period of one month at 40°C/75%R. as per in-house specifications. The stability studies confirmed that there was no significant difference over the testing period with respect to dissolution profile, assay and other physical parameters thus satisfying in-house specifications. In vivo pharmacokinetic studies in Rabbit animal model was carried out for best formulation B3.The pharmacokinetic parameters are summarized in table 11.
CONCLUSION:
From present study, it can be concluded that bilayer tablet dosage form is an ideal fixed dosage form for formulating combination of drugs. Bilayer tablet containing Nebivolol Hydrochloride and Valsartan in immediate release and sustained release layers respectively would be a novel concept in treating hypertension. I formulation point of view precompression and Post compression parameters suggests that, this formulae of drug and excipient combination would provide a satisfactory results.
The immediate release layer of Nebivolol Hydrochloride helps in the immediate release of the drug which acts as loading dose to reduce hypertension initially. The modified release of Valsartan in Sustained release layer is helpful in maintaining the drug levels above the minimum required concentration for a long duration. This reduces dosing frequency from twice a day to once a day. Hence this technology can be used to formulate fixed dosage form of Nebivolol Hydrochloride and Valsartan which can give an optimal therapy for hypertension. The IVIVC suggests a moderate linearity between the In vitro and In vivo results. These findings could be substantiated by further pharmacodynamic evaluation.
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